Keywords: gsk, licenses, candidate, therapeutic, ab, op-r003, eusa
GSK licenses candidate therapeutic Ab OP-R003 from EUSA and Vaccinex for $44M
Article | 25 February 2008
UK-based drug major GlaxoSmithKline has licensed rights to OP-R003, a human anti-interleukin-6 antibody, from fellow UK-based EUSA Pharma for $44.0 million. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
